JPC
NBRV

Jackson Park Capital’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Jackson Park Capital’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-104
Closed -$185K – 46
2016
Q3 		$185K Hold
104
– – 0.24% 43
2016
Q2 		$195K Buy
+104
New +$210K 0.27% 41

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Jackson Park Capital's NBRV Position: Q4 2016 in Review

Jackson Park Capital sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q4 2016, closing a stake of 104 shares — an estimated $185K sold.

Jackson Park Capital first reported a position in NBRV in Q2 2016 and held it in 2 quarters. The position peaked at $195K in Q2 2016. 23 funds tracked by Wall St. Rank hold NBRV as of Q4 2016.

  • Jackson Park Capital reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q4 2016 after selling out during the quarter.
  • Jackson Park Capital sold 104 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q4 2016, an estimated $185K.
  • Jackson Park Capital first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q2 2016 and held it in 2 quarters.
  • Jackson Park Capital's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $195K in Q2 2016.
  • 23 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q4 2016.

Based on Jackson Park Capital's 13F filing for Q4 2016, filed 1 Feb 2017.